Quality Indicators for Healthcare PathwayDELIQUA-CNVNCT07428382
Development and Validation of Care Pathway Quality Indicators for Stroke and Chronic Coronary Syndrome Using French Administrative Healthcare Database (DELIQUA-CNV)
An observational study of Quality Indicators for Healthcare Pathway and Stroke, run by University Hospital, Bordeaux at 2 sites in France.
Trial summary
Cardio-neurovascular diseases are common and costly conditions with care pathways that require optimization. This project aims to develop quality indicators from the French national healthcare database, that are easily deployable and measurable at the national level to improve patient care pathways for both stroke and… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Quality Indicators for Healthcare Pathway, Stroke, Chronic Coronary Syndrome
- How many people
- 36,250 participants
- Where
- 2 sitesFrance
- Study dates
- 20 Jul 2023to 31 Dec 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: To develop these indicators, three population-based cohorts for each care pathway will be derived from cardio-neurovascular registers in Nouvelle-Aquitaine region. The first cohort will be obtained from the interventional cardiology registry for (ACIRA) covering the period from 2017 to 2021. The second cohort will be based on the Aquitaine Observatory of Stroke - Acute phase module (OBA2) for the years 2019 to 2021. The third cohort will focus on post-stroke consultation between July 2022 and December 2023 extraced from OBA2 - Post consulation module. These cohorts will be linked to data from the SNDS, utilizing an indirect deterministic matching approach. These linked databases will serve as the primary reference for validating the quality indicators. These validated indicators will subsequently play a key role in refining care practices and advancing the implementation of quality-based financing models within the healthcare system.
Who may be able to join
- Patient being over 18 years of age living in metropolitan France;
- Patients underwent coronary angiography or PCI between January 2017 and December 2021 for an indication of CCS (stable angina, silent ischemia, other ischemia) at one of the 11 interventional cardiology centers in Aquitaine;
- Patient being over 18 years of age living in metropolitan France;
- Patients treated between January 2019 and December 2021 for a recent stroke (less than 15 days) with clear onset (sudden onset, focal nature of the neurological deficit, confirmation by brain imaging - CT scan or MRI - showing a vascular origin, either ischemic or hemorrhagic, consistent with the clinical presentation) at one of the 16 healthcare facilities in Nouvelle-Aquitaine that treat more than 30 strokes per year.
- Patient being over 18 years of age living in metropolitan France;
- Patients who benefited from post-stroke consultation between July 2022 and December 2023 following a recent completed stroke (sudden onset, focal nature of the neurological deficit, confirmation by brain imaging - CT scan or MRI - showing a vascular origin, either ischemic or hemorrhagic, consistent with the clinical presentation) within one year after the acute episode,
Who cannot join
- Patients refused to participate in the ACIRA registry (The ACIRA registry is an on-going, multicenter, prospective, exhaustive cohort study of patients who undergo coronary angiography or PCI in eleven interventional cardiology centers in the french Aquitaine region);
- Patients who died during the index hospitalization
- Patients with ACIRA stays not matched with SNDS data
- Patients refused to participate in the Aquitaine Observatory of stroke of patients diagnosed with a confirmed ischemic or hemorrhagic stroke (OBA2 registry - Acute phase module)
- Patients treated for rehabilitation of sequelae or complications of a recent stroke (less than 15 days), transient ischemic attack (TIA), or any other neurological condition (meningeal hemorrhage, traumatic intracranial hemorrhage, brain tumor, etc.)
- Patients who died during the index hospitalization
Show all 10Show fewer
- Patients transferred to another facility not participating in ObA2
- Patients with ObA2 stays not matched with SNDS data
- Patients refused to participate in the OBA2 registry registry (The Aquitaine Observatory of stroke of patients diagnosed with a confirmed ischemic or hemorrhagic stroke - Multidisciplinary post-stroke consultation) (OBA2 registry - Post-consulation module)
- Patients treated for rehabilitation of sequelae or complications of a recent stroke (less than 15 days), transient ischemic attack (TIA), or any other neurological condition (meningeal hemorrhage, traumatic intracranial hemorrhage, brain tumor, ...);
Trial locations and contacts
2 sites in 1 country.
About this study
Official title: Development and Validation of Quality Indicators for the Care Pathways of Patients With Stroke and Chronic Coronary Syndrome: Using Practice Registers as Tools for Validating Algorithms Developed From French National Healthcare Databases
Cardio-neurovascular diseases are common and costly conditions with care pathways that require optimization. This project aims to develop quality indicators from the French national healthcare database, that are easily deployable and measurable at the national level to improve patient care pathways for both stroke and Chronic Coronary Syndrome
Read the detailed description
As part of the reform of the French healthcare system, financing models will be adjusted to better account for the quality, safety, and relevance of care, promote coordination among healthcare providers, and establish standardized care pathways. To this end, quality indicators for care pathways are expected for ten priority chronic conditions, including Chronic Coronary Syndromes (CCS) and stroke. These indicators will play a central role in the evaluation of the new quality-based financing system, which focuses on patient care pathways. The DELIQUA-CNV project aims to develop and validate four quality indicators for CCS and stroke care pathways based on data from the French National Health Data System (SNDS).
Readmission following percutaneous coronary intervention (PCI) represents a significant source of healthcare costs and serves as a key indicator of care quality. While readmissions for planned PCI, often driven by activity-based costing models, raise concerns regarding their relevance, they also contribute to increased patient risks and higher healthcare expenses. On the other hand, emergency readmissions after an outpatient procedure serve as a crucial safety indicator for ambulatory care practices. As such, the two key indicators for the CCS care pathway are: 1) Readmission for a new scheduled PCI following an initial PCI for CCS (Sched Re-PCI), and 2) Readmission for a new emergency PCI or coronary angiography following an ambulatory PCI for CCS (Outp Emerg Re-PCI).
The post-stroke phase is crucial, as challenges in referring patients to appropriate rehabilitation facilities often results in gaps and disparities in access to care. These gaps disrupt the continuity of the care pathway. Multi-professional post-stroke consultations are essential for assessing consequences of the stroke and ensuring the delivery of appropriate care. Therefore, the selected indicators for the stroke care pathway are intended to strengthen the organization and quality of care during the post-acute phase: 3) Post-hospitalization orientation during the acute phase according to stroke severity (Stroke_Orient), 4) Identification of multidisciplinary post-stroke consultations between 2 and 6 months after the acute phase (Post-stroke_Cnslt).
To develop these indicators, three population-based cohorts for each care pathway will be derived from cardio-neurovascular registers in Nouvelle-Aquitaine region. The first cohort will be obtained from the interventional cardiology registry for (ACIRA) covering the period from 2017 to 2021. The second cohort will be based on the Aquitaine Observatory of Stroke - Acute phase module (OBA2) for the years 2019 to 2021. The third cohort will focus on post-stroke consultation between July 2022 and December 2023 extraced from OBA2 - Post consulation module. These cohorts will be linked to data from the SNDS, utilizing an indirect deterministic matching approach. These linked databases will serve as the primary reference for validating the quality indicators. These validated indicators will subsequently play a key role in refining care practices and advancing the implementation of quality-based financing models within the healthcare system.
- Being tested
- No intervention (data matching only)
- Keywords
- Quality indicators for healthcare pathway, Stroke, Chronic Coronary Syndrome, Validation, French National Healthcare Data System, Practices registries
- Medical subject headings
- Stroke
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
No intervention (data matching only)Other
These cohorts were linked to data from the SNDS, utilizing an indirect deterministic matching approach. These linked databases serve as the primary reference for validating the quality indicators.
| Study group | Role | What they receive |
|---|---|---|
| CCS Cohort (January 2017- December 2021) | Adult patients (≥18 years) living in metropolitan France who underwent a percutaneous coronary intervention (PCI) between January 2017 and December 2021 for an indication of chronic coronary syndrome (stable angina, silent ischemia, or other ischemia) in one of the eleven interventional cardiology centers in the Aquitaine region.
Detailed inclusion and exclusion criteria for each cohort are provided in the Eligibility Criteria section below. Receives: Other: No intervention (data matching only) | |
| Post-stroke orientation cohort (January 2019- December 2021) | Adult patients (≥18 years) living in metropolitan France who were treated between January 2019 and December 2021 for an acute ischemic or hemorrhagic stroke with a clearly defined onset (within 15 days), confirmed by brain imaging (CT scan or MRI), were included. Patients were managed in one of the eighteen healthcare facilities participating in the Nouvelle-Aquitaine Stroke Observatory (ObA2).
Detailed inclusion and exclusion criteria for each cohort are provided in the Eligibility Criteria section below. Receives: Other: No intervention (data matching only) | |
| Post-stroke consultation cohort cohort (July 2022- December 2023) | Adult patients (≥18 years) living in metropolitan France who underwent a multidisciplinary post-stroke consultation between July 2022 and December 2023 following a completed ischemic or hemorrhagic stroke confirmed by brain imaging (CT scan or MRI), within one year after the acute episode, were included. Patients were managed in one of the nineteen healthcare facilities participating in the Nouvelle-Aquitaine Stroke Observatory (ObA2).
Detailed inclusion and exclusion criteria for each cohort are provided in the Eligibility Criteria section below. Receives: Other: No intervention (data matching only) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Criterion validity - sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of SNDS-based quality indicators for Chronic Coronary Syndrome and Stroke care pathways
The calculation and performance of quality indicators derived from SNDS will be assessed by comparison with practice registries, which will be used as the gold standard. Indicator performance will be quantified using sensitivity, specificity, PPV, and NPV.
The evaluated SNDS-based quality indicators include:
- Readmission for a new scheduled PCI following an initial PCI for CCS (Sched Re-PCI).
- Readmission for a new emergency PCI or coronary angiography following an ambulatory PCI for CCS (Outp Emerg Re-PCI).
- Immediate post-hospital rehabilitation pathway after stroke, in accordance with the orientation criteria recommended by the French National Authority for Health (HAS) in 2020 (Post-stroke_Orient).
- Identification of multidisciplinary post-stroke consultations between 2 and 6 months after the acute phase (Post-stroke_Cnslt).
Measured: 2017-2021 for CCS indicators ; 2019-2021 for post-stroke orientation indicator; 2022-2023 for post-stroke consultation indicator
Secondary outcomes (4)
Construct validity - statistical associations between SNDS-based quality indicators and external indicators of care processes for CCS and stroke
This outcome measure evaluates the construct validity of SNDS-based quality indicators by assessing their statistical associations with external indicators reflecting similar care processes, when available. Construct validity will be quantified using correlation coefficients and comparative statistical analyses between SNDS-based indicators and external reference indicators.
Measured: 2017-2021 for CCS indicators ; 2019-2021 for post-stroke orientation indicator; 2022-2023 for post-stroke consultation indicator
Discriminatory validity - geographic variation in SNDS-based quality indicator values for Chronic Coronary Syndrome and Stroke care pathways
This outcome measure evaluates the ability of SNDS-based quality indicators to discriminate across geographic areas by analyzing variation in indicator values between healthcare facilities. Variation will be assessed using funnel plots and league tables, and results will be reported at the facility level.
Measured: 2017-2021 for CCS indicators ; 2019-2021 for post-stroke orientation indicator; 2022-2023 for post-stroke consultation indicator
Acceptability - usability and interpretability of SNDS-based quality indicators for institutional reporting
Acceptability will be assessed by evaluating the usability and interpretability of indicator results when displayed for institutional and regulatory reporting purposes
Measured: 2017-2021 for CCS indicators ; 2019-2021 for post-stroke orientation indicator; 2022-2023 for post-stroke consultation indicator
Sensitivity to change - temporal trends in SNDS-based quality indicator values for Chronic Coronary Syndrome and Stroke care pathways
This outcome measure evaluates the ability of SNDS-based quality indicators to detect change over time by analyzing temporal trends in indicator values across the study period. Changes over time will be assessed using statistical modeling methods to estimate trends and identify significant variations in indicator values.
Measured: 2017-2021 for CCS indicators ; 2019-2021 for post-stroke orientation indicator; 2022-2023 for post-stroke consultation indicator
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Feb 2026
- Study start20 Jul 2023
- Primary completion31 Dec 2025
- Study completion31 Dec 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Quality Indicators for Healthcare PathwayStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 36,250 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital, Bordeaux
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- EMILIE LESAINE, Principal investigator, University Hospital, Bordeaux
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07428382
- Sponsor's protocol ID
- CHUBX 2021/57
- Acronym
- DELIQUA-CNV
- Status last verified
- Feb 2026
- First submitted
- 9 Dec 2025
- Last updated
- 23 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Development and Validation of Quality Indicators for the Care Pathways of Patients With Stroke and Chronic Coronary Syndrome: Using Practice Registers as Tools for Validating Algorithms Developed From French National Healthcare Databases
- ClinicalTrials.gov ID
- NCT07428382
- Acronym / sponsor ID
- DELIQUA-CNV / CHUBX 2021/57
- Keywords
- Quality indicators for healthcare pathway, Stroke, Chronic Coronary Syndrome, Validation, French National Healthcare Data System, Practices registries
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 36,250 participants (actual)
- Lead sponsor
- University Hospital, BordeauxUniversity, hospital or other
- Study start
- 20 Jul 2023 (actual)
- Primary completion
- 31 Dec 2025 (actual)
- Study completion
- 31 Dec 2025 (actual)
- First posted
- 23 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Cardio-neurovascular diseases are common and costly conditions with care pathways that require optimization. This project aims to develop quality indicators from the French national healthcare database, that are easily deployable and measurable at the national level to improve patient care pathways for both stroke and Chronic Coronary Syndrome
Detailed description
As part of the reform of the French healthcare system, financing models will be adjusted to better account for the quality, safety, and relevance of care, promote coordination among healthcare providers, and establish standardized care pathways. To this end, quality indicators for care pathways are expected for ten priority chronic conditions, including Chronic Coronary Syndromes (CCS) and stroke. These indicators will play a central role in the evaluation of the new quality-based financing system, which focuses on patient care pathways. The DELIQUA-CNV project aims to develop and validate four quality indicators for CCS and stroke care pathways based on data from the French National Health Data System (SNDS).
Readmission following percutaneous coronary intervention (PCI) represents a significant source of healthcare costs and serves as a key indicator of care quality. While readmissions for planned PCI, often driven by activity-based costing models, raise concerns regarding their relevance, they also contribute to increased patient risks and higher healthcare expenses. On the other hand, emergency readmissions after an outpatient procedure serve as a crucial safety indicator for ambulatory care practices. As such, the two key indicators for the CCS care pathway are: 1) Readmission for a new scheduled PCI following an initial PCI for CCS (Sched Re-PCI), and 2) Readmission for a new emergency PCI or coronary angiography following an ambulatory PCI for CCS (Outp Emerg Re-PCI).
The post-stroke phase is crucial, as challenges in referring patients to appropriate rehabilitation facilities often results in gaps and disparities in access to care. These gaps disrupt the continuity of the care pathway. Multi-professional post-stroke consultations are essential for assessing consequences of the stroke and ensuring the delivery of appropriate care. Therefore, the selected indicators for the stroke care pathway are intended to strengthen the organization and quality of care during the post-acute phase: 3) Post-hospitalization orientation during the acute phase according to stroke severity (Stroke_Orient), 4) Identification of multidisciplinary post-stroke consultations between 2 and 6 months after the acute phase (Post-stroke_Cnslt).
To develop these indicators, three population-based cohorts for each care pathway will be derived from cardio-neurovascular registers in Nouvelle-Aquitaine region. The first cohort will be obtained from the interventional cardiology registry for (ACIRA) covering the period from 2017 to 2021. The second cohort will be based on the Aquitaine Observatory of Stroke - Acute phase module (OBA2) for the years 2019 to 2021. The third cohort will focus on post-stroke consultation between July 2022 and December 2023 extraced from OBA2 - Post consulation module. These cohorts will be linked to data from the SNDS, utilizing an indirect deterministic matching approach. These linked databases will serve as the primary reference for validating the quality indicators. These validated indicators will subsequently play a key role in refining care practices and advancing the implementation of quality-based financing models within the healthcare system.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| CCS Cohort (January 2017- December 2021) | – | Other: No intervention (data matching only)Adult patients (≥18 years) living in metropolitan France who underwent a percutaneous coronary intervention (PCI) between January 2017 and December 2021 for an indication of chronic coronary syndrome (stable angina, silent ischemia, or other ischemia) in one of the eleven interventional cardiology centers in the Aquitaine region. Detailed inclusion and exclusion criteria for each cohort are provided in the Eligibility Criteria section below. |
| Post-stroke orientation cohort (January 2019- December 2021) | – | Other: No intervention (data matching only)Adult patients (≥18 years) living in metropolitan France who were treated between January 2019 and December 2021 for an acute ischemic or hemorrhagic stroke with a clearly defined onset (within 15 days), confirmed by brain imaging (CT scan or MRI), were included. Patients were managed in one of the eighteen healthcare facilities participating in the Nouvelle-Aquitaine Stroke Observatory (ObA2). Detailed inclusion and exclusion criteria for each cohort are provided in the Eligibility Criteria section below. |
| Post-stroke consultation cohort cohort (July 2022- December 2023) | – | Other: No intervention (data matching only)Adult patients (≥18 years) living in metropolitan France who underwent a multidisciplinary post-stroke consultation between July 2022 and December 2023 following a completed ischemic or hemorrhagic stroke confirmed by brain imaging (CT scan or MRI), within one year after the acute episode, were included. Patients were managed in one of the nineteen healthcare facilities participating in the Nouvelle-Aquitaine Stroke Observatory (ObA2). Detailed inclusion and exclusion criteria for each cohort are provided in the Eligibility Criteria section below. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- To develop these indicators, three population-based cohorts for each care pathway will be derived from cardio-neurovascular registers in Nouvelle-Aquitaine region. The first cohort will be obtained from the interventional cardiology registry for (ACIRA) covering the period from 2017 to 2021. The second cohort will be based on the Aquitaine Observatory of Stroke - Acute phase module (OBA2) for the years 2019 to 2021. The third cohort will focus on post-stroke consultation between July 2022 and December 2023 extraced from OBA2 - Post consulation module. These cohorts will be linked to data from the SNDS, utilizing an indirect deterministic matching approach. These linked databases will serve as the primary reference for validating the quality indicators. These validated indicators will subsequently play a key role in refining care practices and advancing the implementation of quality-based financing models within the healthcare system.
Key inclusion criteria (6 listed)
- Patient being over 18 years of age living in metropolitan France;
- Patients underwent coronary angiography or PCI between January 2017 and December 2021 for an indication of CCS (stable angina, silent ischemia, other ischemia) at one of the 11 interventional cardiology centers in Aquitaine;
- Patient being over 18 years of age living in metropolitan France;
- Patients treated between January 2019 and December 2021 for a recent stroke (less than 15 days) with clear onset (sudden onset, focal nature of the neurological deficit, confirmation by brain imaging - CT scan or MRI - showing a vascular origin, either ischemic or hemorrhagic, consistent with the clinical presentation) at one of the 16 healthcare facilities in Nouvelle-Aquitaine that treat more than 30 strokes per year.
- Patient being over 18 years of age living in metropolitan France;
Key exclusion criteria (10 listed)
- Patients refused to participate in the ACIRA registry (The ACIRA registry is an on-going, multicenter, prospective, exhaustive cohort study of patients who undergo coronary angiography or PCI in eleven interventional cardiology centers in the french Aquitaine region);
- Patients who died during the index hospitalization
- Patients with ACIRA stays not matched with SNDS data
- Patients refused to participate in the Aquitaine Observatory of stroke of patients diagnosed with a confirmed ischemic or hemorrhagic stroke (OBA2 registry - Acute phase module)
- Patients treated for rehabilitation of sequelae or complications of a recent stroke (less than 15 days), transient ischemic attack (TIA), or any other neurological condition (meningeal hemorrhage, traumatic intracranial hemorrhage, brain tumor, etc.)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| No intervention (data matching only)These cohorts were linked to data from the SNDS, utilizing an indirect deterministic matching approach. These linked databases serve as the primary reference for validating the quality indicators. | Other | CCS Cohort (January 2017- December 2021), Post-stroke consultation cohort cohort (July 2022- December 2023), Post-stroke orientation cohort (January 2019- December 2021) |
Primary outcome
Criterion validity - sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of SNDS-based quality indicators for Chronic Coronary Syndrome and Stroke care pathways
Time frame: 2017-2021 for CCS indicators ; 2019-2021 for post-stroke orientation indicator; 2022-2023 for post-stroke consultation indicator
The calculation and performance of quality indicators derived from SNDS will be assessed by comparison with practice registries, which will be used as the gold standard. Indicator performance will be quantified using sensitivity, specificity, PPV, and NPV. The evaluated SNDS-based quality indicators include: * Readmission for a new scheduled PCI following an initial PCI for CCS (Sched Re-PCI). * Readmission for a new emergency PCI or coronary angiography following an ambulatory PCI for CCS (Outp Emerg Re-PCI). * Immediate post-hospital rehabilitation pathway after stroke, in accordance with the orientation criteria recommended by the French National Authority for Health (HAS) in 2020 (Post-stroke_Orient). * Identification of multidisciplinary post-stroke consultations between 2 and 6 months after the acute phase (Post-stroke_Cnslt).
4 secondary outcomes
Construct validity - statistical associations between SNDS-based quality indicators and external indicators of care processes for CCS and stroke
Time frame: 2017-2021 for CCS indicators ; 2019-2021 for post-stroke orientation indicator; 2022-2023 for post-stroke consultation indicator
Discriminatory validity - geographic variation in SNDS-based quality indicator values for Chronic Coronary Syndrome and Stroke care pathways
Time frame: 2017-2021 for CCS indicators ; 2019-2021 for post-stroke orientation indicator; 2022-2023 for post-stroke consultation indicator
Acceptability - usability and interpretability of SNDS-based quality indicators for institutional reporting
Time frame: 2017-2021 for CCS indicators ; 2019-2021 for post-stroke orientation indicator; 2022-2023 for post-stroke consultation indicator
Sensitivity to change - temporal trends in SNDS-based quality indicator values for Chronic Coronary Syndrome and Stroke care pathways
Time frame: 2017-2021 for CCS indicators ; 2019-2021 for post-stroke orientation indicator; 2022-2023 for post-stroke consultation indicator
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Feb 2026.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
EMILIE LESAINE principal investigator
University Hospital, Bordeaux
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Quality Indicators for Healthcare Pathway and Stroke, run by University Hospital, Bordeaux at 2 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 23 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Criterion validity - sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of SNDS-based quality indicators for Chronic Coronary Syndrome and Stroke care pathways (time frame: 2017-2021 for CCS indicators ; 2019-2021 for post-stroke orientation indicator; 2022-2023 for post-stroke consultation indicator). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Feb 2026.